Advanced Solid Tumors, Cervical Cancer, Colorectal Cancer, EGFR Positive Solid Tumor, Gastric Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, HER2-positive Breast Cancer, Lymphoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability, NSCLC, Pancreas Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Conditions
Keywords
Advanced Solid Tumor, Lymphoma, Breast Cancer, Head and Neck Cancer, Head and Neck, Squamous Cell Carcinoma, Gastric Cancer, Colorectal Cancer, Immunotherapy, NK cell therapy, Melanoma, Checkpoint Inhibitor, Immune Checkpoint Inhibitor, Monoclonal Antibody, Cell therapy, Cellular therapy, nivolumab, pembrolizumab, atezolizumab
Brief summary
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.
Interventions
DRUGFT500
FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
DRUGNivolumab
Immune Checkpoint Inhibitor
DRUGPembrolizumab
Immune Checkpoint Inhibitor
DRUGAtezolizumab
Immune Checkpoint Inhibitor
DRUGCyclophosphamide
Lympho-conditioning agent
DRUGFludarabine
Lympho-conditioning agent
DRUGIL-2
Biologic response modifier
Sponsors
Fate Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1\. Diagnosis of the following, as per Regimen Cohort: 1A. Regimen A: FT500 Monotherapy (Dose Escalation): An advanced solid tumor malignancy, including lymphoma, in a participant who has failed or refused available FDA-approved therapies and is now a candidate for salvage therapy. 1B. Regimen B and BB (Dose Escalation): FT500 (+ IL-2, Regimen BB only) + ICI: An advanced solid tumor malignancy, including lymphomas, that has progressed on treatment with at least one ICI (ie, nivolumab, pembrolizumab or atezolizumab), in a participant who has also failed or refused other available approved therapies and is now a candidate for salvage therapy. 1C. Regimen B(Dose Expansion): FT500 (+ IL-2, Regimen BB only) + ICI An advanced solid tumor malignancy or lymphoma in a participant with disease relapse or progression on an ICI (nivolumab, pembrolizumab, or atezolizumab) in an approved indication per the respective USPI. 2\. Willingness to provide informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. 3\. Age \>18 years old at the time of signing the ICF. 4. Presence of measurable disease by iRECIST or RECIL criteria, assessed before the start of lympho-conditioning and within 28 days prior to Day 1. 5\. Contraceptive use by women or men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 5a. Female participants: Women of childbearing potential (WOCBP) must use a highly effective form of contraception from the screening visit until at least 12 months after the final dose of CY, at least 4 months after the final dose of FT500, at least 4 months after the final dose of pembrolizumab, and at least 5 months after the final dose of nivolumab or atezolizumab, whichever is latest. 5b. Male participants: Males must be sterile (biologically or surgically) or use a highly effective method of contraception from the screening visit until at least 14 months after the final dose of CY, at least 6 months after the final dose of FT500, at least 6 months after the final dose of pembrolizumab, and at least 7 months after the final dose of nivolumab or atezolizumab, whichever is latest. 6\. Willingness to comply with study procedures through the planned study duration. For patients with \>1 measurable lesion, agreement to undergo a biopsy from a safely accessible site per Investigator assessment for exploratory biomarker assessments. 7\. Provision of signed and dated ICF to agree to participate, at time of withdrawal or completion of this study, in Fate Therapeutics' long-term, non-interventional, observational study, FT-003.
Exclusion criteria
All participants: 1\. Females who are pregnant or breastfeeding. 2. ECOG performance status ≥ 2. 3. Evidence of insufficient organ function as determined by any one of the following: 3a. Neutrophils \<1000/µL or platelets \<75,000/µL. 3b. Estimated creatinine clearance \<50 mL/minute (Cockcroft-gault). 3c. Total bilirubin \>2 x upper limit normal (ULN) with the exception of participants with Gilbert's Syndrome or known liver metastases. 3d. Aspartate aminotransferase (AST) \>3 x ULN, or alanine aminotransferase (ALT) \>3 x ULN. For participants with known liver metastases, AST or ALT \>5 x ULN. 3e. Oxygen saturation \<90% on room air. 3f. Left ventricular ejection fraction (LVEF) \<40% (eg by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan). 4.Receipt of any biological therapy, chemotherapy, or radiation (except palliative radiation) within 2 weeks prior to Day 1. Participants in Regimen B currently taking an ICI must interrupt ICI dosing at least 2 weeks prior to Day 1. 5\. CNS metastases that have not been treated; or treated CNS metastases that have not been stable for at least 4 weeks. 6\. Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first study medication; or the presence of unstable angina or congestive heart failure of New York Heart Association grade 2 or higher. 7\. Currently receiving or likely to require systemic immunosuppressive therapy (eg, prednisone \>5 mg daily) for any reason from Day -7 to Day 29. 8\. Uncontrolled infections. 9. Known allergy to the following FT500 components: Albumin (Human) or DMSO. 10. Presence of any medical or social issues that are likely to interfere with study conduct, or may cause increased risk to participant. 11\. Any medical condition or clinical laboratory abnormality that, per Investigator or Medical Monitor judgement, precludes safe participation in and completion of the study, or that could affect compliance with protocol conduct or interpretation of results. Participants who have had prior receipt of a Fate Therapeutics investigational human iPSC product may be eligible for the study with approval from the Medical Monitor. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort. | Day 29 | The incidence of participants with DLTs within each assessed dose level cohort to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective-response rate (ORR) | Day 29 and every 8 weeks thereafter through Day 366 | ORR is defined as the proportion of participants who achieve immune partial reponse/partial response (iPR/PR) or immune complete response/complete response (iCR/CR). Tumor response will be assessed using modified Response Evaluation Criteria in Solid Tumors (iRECIST) or Response Evaluation Criteria in Lymphoma (RECIL), as applicable. |
| Duration of FT500 persistence | Day 1 through Day 366 | Duration of FT500 response is defined as duration from Day 1 to undetectable levels of FT500 cells per uL blood. |
Countries
United States
Outcome results
None listed